Eye Research Foundation | Newport Beach, CA

Research site

(Unclaimed)

Location

520 Superior Avenue, Suite 235, Newport Beach, California, United States of America

Site insights

Top conditions

Top treatments

Bimatoprost

Latanoprost

AR-15512

AMDX-2011P

Pilocarpine HCl

AGN-195263

K-161

DE-117

MT10109L

KPI-121

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

13 of 76 total trials

A Phase 3 Study to Evaluate AZR-MD-001 in Patients with Abnormal Meibomian Gland Function and Dry Eye Disease (DED)

This study is a multicenter, double-masked, vehicle-controlled, randomized, parallel group study designed to evaluate the treatment of abnormal meibo...

Active, not recruiting

Dry Eye Disease

Other: Vehicle

Drug: AZR-MD-001

A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes

A randomized, double-blind, parallel-group, two-arm, multiple dose, multicenter, clinical endpoint bioequivalence study

Enrolling

Open-angle Glaucoma

Ocular Hypertension

Drug: LUMIGAN® (bimatoprost ophthalmic solution) 0.01%

Drug: Bimatoprost Ophthalmic Solution, 0.01%

A Study of AMDX-2011P in Participants With Alzheimer's Disease

The purpose of this study is to assess safety, tolerability, plasma pharmacokinetics and biologic activity of a single intravenous dose of AMDX-2011P...

Enrolling

Alzheimer Disease

Drug: AMDX-2011P

A Study of AMDX-2011P in Participants With CAA

The purpose of this study is to assess safety, tolerability, plasma pharmacokinetics and biologic activity of a single intravenous dose of AMDX-2011P...

Enrolling

Cerebral Amyloid Angiopathy

Drug: AMDX-2011P

A Study of AMDX-2011P in Participants With Primary Open Angle Glaucoma

The purpose of this research study is to assess the ability of AMDX- 2011P to identify amyloid deposits in the retina of participants with Primary Op...

Enrolling

Primary Open Angle Glaucoma

Drug: AMDX-2011P

AMDX-2011P Retinal Tracer in Subjects With Neurodegenerative Diseases Associated With Amyloidogenic Proteinopathy (PROBE)

The purpose of this research study is to assess safety and tolerability of a single intravenous (given through a vein) dose of the investigational re...

Enrolling

Parkinson Disease

Amyotrophic Lateral Sclerosis

Drug: AMDX2011P

Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.

This is a randomized, double-blind, two-treatment, single-period, parallel design, multiple dose at multiple clinical trial sites designed to demonst...

Enrolling

Ocular Hypertension

Glaucoma, Open-Angle

Drug: Test - Bimatoprost 0.01% Ophthalmic Solution

Drug: Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution)

Locations recently updated

Efficacy and Safety Assessment of T4090 Ophthalmic Solution Versus Rhopressa® Ophthalmic Solution in Patients with Open-angle Glaucoma or Ocular Hypertension

The main purpose is to compare the ocular hypotensive efficacy and safety of two concentrations of T4090 (Kinezodianone R HCl 0.2% and 0.3%) ophthalm...

Active, not recruiting

Glaucoma

Ocular Hypertension

Drug: Rhopressa®

Drug: T4090 0.3%

MRCT Evaluating NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension (Denali)

The objective of this clinical study is to evaluate the safety and efficacy of NCX 470 Ophthalmic Solution in lowering intraocular pressure (IOP) in...

Enrolling

Open Angle Glaucoma

Ocular Hypertension

Drug: Latanoprost 0.005%

Drug: NCX 470 0.1%

Next Generation Rocklatan

The purpose of this two-stage clinical trial is to assess the safety and hypotensive efficacy of AR-17043 and PG043 ophthalmic solutions in subjects...

Enrolling

Open Angle Glaucoma

Ocular Hypertension

Drug: AR-17043 Ophthalmic Solution

Drug: Netarsudil 0.02%/Latanoprost 0.005% Ophthalmic Solution

Open-Label Study of Safety of H1337 in Healthy Volunteers

The trial will evaluate the safety of one dose regimen of H-1337 \[1% twice daily (b.i.d.)\] in both eyes in healthy volunteers.

Enrolling

Glaucoma Open-Angle Primary

Ocular Hypertension

Drug: H-1337 1.0%

Prospective, Randomized, Masked, Controlled Trial To Evaluate The Safety And Effectiveness Of The TearCare® System In The Treatment Of The Signs And Symptoms Of Dry Eye Disease (SAHARA)

To demonstrate the safety and effectiveness of TearCare® procedures compared to Restasis® to treat the signs and symptoms of dry eye disease in adult...

Active, not recruiting

Dry Eye

Meibomian Gland Dysfunction

Device: TearCare System

Drug: Restasis